DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20204863

Lymphocyte-monocyte ratio as predictive factors for huvos scores in osteosarcoma extremities treated by neoadjuvan chemotherapy (cisplatin and doxorubicin)

I. Made Tusan Sidharta, I. Ketut Siki Kawiyana, I. Ketut Suyasa

Abstract


Background: Chemotherapy is a vital treatment in osteosarcoma but it’s responses are difficult to predict, and there are still no biomarkers that can estimate the prognosis of chemotherapy. Lymphocytes and monocytes are key immune cells which are examined on complete blood count test before chemotherapy and often associated with prognosis of various malignancies. Low lymphocyte-monocyte ratio (LMR) are associated with poor prognostics in some cancers.

Methods: This study is cross-sectional retrospective analytics that was conducted at Sanglah Hospital from June to August 2018. The research subject was medical records of intramedullary conventional osteosarcoma patients which fulfil inclusion and exclusion criteria. In this study, LMR as independent variable and Huvos score as dependent variable.

Results: The result in this study showed positive correlation between LMR before neoadjuvan Chemotherapy and Huvos score (r=0.500) with p<0.05.

Conclusions: A positive correlation was found between LMR and Huvos scores. Low LMR before neoadjuvan chemotheraphy (<2.81) were correlated with low huvos scores (grade I and II).


Keywords


Osteosarcoma, Lymphocyte-monocyte ratio, Huvos score

Full Text:

PDF

References


Wittig JC, Bickels J, Priebat D. Osteosarcoma: A multidisciplinary approach to diagnosis and treatment. American Family Physician. 2002;65(6):1123-32.

Ritter J, Bielack SS. Osteosarcoma. In: Annals of Oncology. 2010;21(7):320-25.

Kamal AF, Widyawarman H, Husodo K. Clinical Outcome and Survival of Osteosarcoma Patients in Cipto Mangunkusumo Hospital: Limb Salvage Surgery versus Amputation. Acta Med Indones. 2019;42:14-48.

Ferrari S, Briccoli A, Mercuri M, et al. Late relapse in osteosarcoma. J Pediatr Hematol Oncol. 2006;28(7):418-22.

Fitzmaurice AG, Rhodes SL, Lulla A. Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease. Proc Natl Acad Sci U S A. 2013;110:636-41.

Franke M, Hardes J, Helmke K, et al. Solitary skeletal osteosarcoma recurrence. Findings from the Cooperative Osteosarcoma Study Group. Pediatr Blood Cancer. 2011;56(5):771-6.

Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. In: Cancer Treatment and Research. 2009;152:3-13.

Zhang Y, Yang J, Zhao N. Progress in the chemotherapeutic treatment of osteosarcoma. Oncology Letters. 2018;16(5):6228-37.

Liu X, Li M, Zhao F. The lymphocyte–monocyte ratio predicts tumor response and survival in patients with locally advanced esophageal cancer who received definitive chemoradiotherapy. Onco Targets Ther. 2017;10:871-77.

Chen D, Liu D, Chen Z. Potential therapeutic implications of miRNAs in osteosarcoma chemotherapy. Tumor Biology. 2017;1-7.

Jiang R, Cai XY, Yang ZH, et al. Elevated peripheral blood lymphocyteto-monocyte ratio predicts a favorable prognosis in the patients with metastatic nasopharyngeal carcinoma. Chin J Cancer. 2015;34(6):237-46.